BETAPREDICT - MS Patients Treated With BETAferon: PREDICTors of Treatment Adherence
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BETAPREDICT
- Sponsors Bayer
- 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2016 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
- 10 Nov 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2019.